Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Dr. Reddy’s Secures Global Licensing Deal to Market Immutep’s Cancer Drug
Under the terms of the deal, Dr. Reddy’s will manage the drug’s development and commercialisation across all international markets except North America, Europe, Japan and Greater China. Immutep will continue to manufacture and supply the therapy for these regions.
- By Newsdesk
- New Delhi
- Dec 08, 2025
Dr. Reddy’s Laboratories has entered into an exclusive global licensing agreement with Australian biotechnology company Immutep to develop, produce and sell its investigational cancer drug, eftilagimod alfa. The partnership is set to significantly strengthen Dr. Reddy’s oncology pipeline and broaden Immutep’s commercial reach.
Under the terms of the deal, Dr. Reddy’s will manage the drug’s development and commercialisation across all international markets except North America, Europe, Japan and Greater China. Immutep will continue to manufacture and supply the therapy for these regions.
The financial structure includes an upfront payment of USD 20 million to Immutep, followed by potential milestone payments of up to USD 349.5 million tied to regulatory approvals, development progress and commercial success. Immutep will also earn double-digit royalties on future sales in the licensed territories.
Eftilagimod alfa, also known as “Efti,” is a first-in-class immunotherapy designed to stimulate the immune system to fight cancer. It is currently in a Phase III trial as a first-line treatment for advanced or metastatic non-small cell lung cancer and is being explored for additional indications such as head and neck cancer, breast cancer and soft-tissue sarcoma.
Dr. Reddy’s said the collaboration aligns with its long-term goal of expanding beyond generics and building a strong presence in innovative oncology treatments. The company believes Efti has the potential to become a breakthrough therapy, especially when used in combination with existing cancer drugs.